Evaluation of stability and simultaneous determination of fimasartan and amlodipine by a HPLC method in combination tablets  by Moon, Hyeon Woo et al.
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 2 3e1 2 8Available online at wScienceDirect
journal homepage: http : / /ees.e lsevier .com/ajps/defaul t .aspOriginal Research PaperEvaluation of stability and simultaneous
determination of fimasartan and amlodipine
by a HPLC method in combination tabletsHyeon Woo Moon a,1, Abid Mehmood Yousaf a,1, Kwan Hyung Cho b,c,
Chul Soon Yong b,***, Jong Oh Kim b,**, Han-Gon Choi a,*
aCollege of Pharmacy, Hanyang University, 1271, Sa-3-Dong, Ansan 426-791, South Korea
bCollege of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan 712-749, South Korea
cCollege of Pharmacy, Inje University, Inje-ro 197 Gimhae 621-749, South Koreaa r t i c l e i n f o
Article history:
Received 6 March 2014
Received in revised form
1 April 2014
Accepted 11 April 2014
Available online 24 April 2014
Keywords:
Fimasartan
Amlodipine
Validation
Stability
HPLC
Combination tablet* Corresponding author. Tel.: þ82 31 400 5802;
** Corresponding author. Tel.: þ82 53 810 281
*** Corresponding author. Tel.: þ82 53 810 281
E-mail addresses: csyong@yumail.ac.kr (C.S.
Peer review under responsibility of Shenyan
Production and hosting by El
1 Both authors contributed equally to this
http://dx.doi.org/10.1016/j.ajps.2014.04.002
1818-0876/ª 2014 Shenyang Pharmaceuticala b s t r a c t
A simple, rapid, accurate, precise and robust HPLC method was developed for the simul-
taneous determination of fimasartan and amlodipine in tablet dosage form. Furthermore,
stability of active ingredients was evaluated under normal and stress conditions. The
isocratic elution was accomplished by Nucleosil C18 column (250 mm  4.6 mm, 5 mm) at
40 C. The mobile phase consisted of acetonitrile and 0.02 M monopotassium phosphate
buffer (pH 2.2) in the ratio of 50:50 (v/v) was eluted at 1.0 ml/min. The eluent was moni-
tored by the UV detector for fimasartan and amlodipine at 237 nm for 8 min, detection
time. The validation of HPLC method was carried out in accordance with the ICH
guidelines.
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Hypertension is the most common primary cause of cardio-
vascular morbidities [1]. Multiple-drug therapy is frequently
prescribed in the treatment of hypertension [2]. Fimasartan
(Fig. 1A) (2-n-butyl-5-dimethylamino-thiocarbonylmethyl-6-
methyl-3, pyrimidin-4(3H)) is a newly developed angiotensin
II type 1 (AT1) receptor blocker [3]. Its safety and efficacy is well
characterized [4]. The Korean Food and Drug Administration
(KFDA) has approved fimasartan as a drug in September 2010
[5]. Fimasartan is tolerable when used concomitantly
with hydrochlorothiazide, digoxin or amlodipine [6e9].
Amlodipine besylate (Fig. 1B) (2-[(2-aminoethoxy)-methyl]-
4-(2-chlorophenyl) 1, 4-dihydro-6-methyl-3,5-pyridine-dicar-
boxylic acid-3 ethyl-5 methyl ester) is a calcium channel
blocker used in the management of hypertension and angina
[10]. A lot of methods have been reported for the determina-
tion of amlodipine alone or in combination with other active
pharmaceutical agents in dosage forms or in biological fluids
[11]. However, simultaneous determination of fimasartan and
amlodipine has not been described previously. The purpose of
present studywas to develop and validate anHPLCmethod for
simultaneous determination of fimasartan and amlodipine in
tablet dosage form. Moreover, stability of active ingredients
was also evaluated by using this method.Fig. 1 e Chemical structure: (A), fimasartan; (B), amlodipine.2. Materials and methods
2.1. Materials
Fimasartan and amlodipine drug powders (as reference
standards) were obtained from Boryung Pharm. Co. (Seoul,
Korea). Fimasartan and amlodipine combination tablets
(60 mg/5 mg) were manufactured by Boryung Pharm. Co.
(Seoul, Korea). Acetonitrile (Avantor Performance Materials,
Inc., Center Valley, PA, USA) was obtained for HPLC analysis.
Monopotassium phosphate was acquired from Daejung
Chemical Co. (Siheung, Korea). Ultrapure water processed
through Milli-Q Advantage A10 Ultrapure Water Purification
System (Millipore, Merck & Co., Inc., Billerica, Middlesex
County, MO, USA) was used to prepare 0.02 Mmonopotassium
phosphate buffer solution. All other chemicals were of reagent
grade.2.2. Instrumentation and chromatographic conditions
The isocratic elution was carried out using an HPLC system
(Waters alliance system; Waters Corporation, Milford, MA,
USA). An aliquot of 20 ml sample was assayed for the simul-
taneous determination of fimasartan and amlodipine. The
mobile phase consisted of acetonitrile and 0.02 M monop-
otassium phosphate buffer solution (pH 2.2) (50:50, volume
ratio) was eluted through Nucleosil C18 column
(250 mm  4.6 mm, 5 mm) (MachereyeNagel GmbH & Co.;
Du¨ren, Germany) at a flow rate of 1.0 ml/min. The column
temperature was 40 C. The eluent was monitored at 237 nm
for detection of fimasartan and amlodipine by the UV detec-
tor. The detection time was 8 min.2.3. Preparation of standard concentrations
2.3.1. Stock solutions
The powdered tablets and the tablet powders equivalent to
10 mg fimasartan or amlodipine were weighed and trans-
ferred to 100 ml measuring flask. These powdered tablets
were weighed after milling the tablet with pestle and
mortar. Each sample was dissolved in 100 ml acetonitrile to
get the stock solution with final strength of 100 mg/ml.
Then, each stock solution was filtered (0.45 mm) before
further use.
2.3.2. Calibration standards
Six standard concentrations with 6, 12, 18, 24, 30 and 36 mg/ml
were prepared from the stock solution of fimasartan drug
powder (pure form). Similarly, six standard strengths with 0.5,
1.0, 1.5, 2.0, 2.5 and 3.0 mg/ml were prepared from the stock
solution of amlodipine drug powder (pure form).
2.3.3. Sample solutions
The standard concentrations with 10, 15 and 30 mg/ml were
derived from the stock solution of fimasartan prepared with
the powdered tablets. Similarly, standard strengths with
0.625, 1.25 and 2.5 mg/mlwere obtained from the stock solution
of amlodipine prepared with the powdered tablets.
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2.4.1. System suitability
The typical values for evaluating system suitability of a
chromatographic procedure include the RSD <1%, tailing
factor <2 and theoretical plates >2000 [12]. The determina-
tion of system suitability of analytical method was accom-
plished by assaying six samples of the same strength of
fimasartan or amlodipine. The sample concentration of fim-
sartan and amlodipine used in this analysis was 10 mg/ml and
0.75 mg/ml, respectively. The retention time, peak area,
theoretical plates and tailing factor were evaluated for sys-
tem suitability.
2.4.2. Sensitivity
The limit of detection (LOD) and quantification limit (LOQ)
were determined by gradually diluting the sample and ana-
lysing by the proposed method. The signal/noise ratio (S/N)
was determined for each tested strength. The typical S/N ratio
recommended by the International Conference on Harmo-
nisation (ICH) is 3/1 and 10/1 for LOD and LOQ, respectively
[13].
2.4.3. Calibration curve
The above-mentioned calibration standardswere analysed for
determining linearity. The sample strengths ranged from 6 to
36 mg/ml and 0.5 to 3.0 mg/ml for fimasartan and amlodipine,
respectively. The regression analysis was accomplished by
slope, intercept and correlation coefficient (r2).
2.4.4. Accuracy and precision
The accuracy was determined by percent recovery method.
Furthermore, precision (inter-day variance and intra-day
variance) were determined by assaying samples over a
period of 1 day and 3 days, respectively. The standard con-
centrations of fimasartan used in this investigation were 10,
15 and 30 mg/ml. And, the standard strengths of amlodipine
used in this study were 0.625, 1.25 and 2.5 mg/ml.Fig. 2 e Chromatogram of fimasartan and amlodipine recorded d
fimasartan and amlodipine were about 2.68 and 5.22 min, resp2.4.5. Robustness
The influence of slight deliberate changes in chromatographic
conditions such as column temperature, flow rate of mobile
phase and pH of mobile phase on the retention time and peak
area were observed one by one. The test was performed in
triplicate for each set of conditions. The standard concentra-
tions of fimasartan and amlodipine used in this analysis were
30 mg/ml and 2.5 mg/ml, respectively.2.5. Stability
2.5.1. Stability in sample solutions
The stability of fimasartan and amlodipine in acetonitrile was
determined by assaying the selected standard concentrations
of these drugs at 1, 2, 4, 8, 16, 32 and 64 h. The standard con-
centrations of fimasartan and amlodipine used in this study
were 30 mg/ml and 2.5 mg/ml, respectively. The samples placed
in the auto-sampler at room temperature were assayed and
peak areas were recorded.
2.5.2. Stability of powdered tablets under stressed conditions
The stability study of fimasartan and amlodipine in powdered
tablets placed under stress environment of temperature,
relative humidity and UV radiations was assessed by % assay
up to 56 days. The effect of temperature on stability of fima-
sartan and amlodipine was evaluated by placing the
powdered tablet samples at 45 C and 60 C separately in Sunil
Eyela KCL 2000 W (Sunil Eyela Co.; Seongnam, Korea). For
testing the stability under hot and humid conditions, the
powdered tablet sample was placed at 40 C and 75% relative
humidity in Sunil Eyela KCL 2000 W (Sunil Eyela Co.; Seong-
nam, Korea). The influence of UV radiations was perused
by placing the sample under 15,000 Lux.hr UV radiations in
Sunil Eyela LST-2000 (Sunil Eyela Co.; Seongnam, Korea). A
powdered tablet sample was also placed at room temperature
and airmoisture to test stability under normal conditions. The
samples were periodically tested for fimasartan and amlodi-
pine content after 14, 28, 42 and 56 days.uring simultaneous determination. The retention times of
ectively.
Table 1 e System suitability parameters.
Component Peak area Retention time Tailing factor Theoretical plates
Fimasartan 8.972  0.055 5.24  0.532 1.62  0.533 4761  0.630
Amlodipine 0.759  0.157 2.63  0.614 1.71  0.584 4621  0.546
Each value denotes the Mean  %RSD (n ¼ 6).
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Hypertension, a chief risk factor for coronary heart disease can
be reduced by proper control of blood pressure. Fimasartan
(Fig. 1A) could reduce blood pressure by inhibiting the binding
of angiotensin II to the angiotensin I receptor in the vascular
smooth muscle, and blocking the vasoconstriction and
aldosterone-secreting effects of angiotension II [10]. Amlodi-
pine (Fig. 1B), a derivative of dihydropyridines, blocks the cal-
cium influx into vascular smooth muscle and cardiac muscle,
leading to decrease inperipheral vascular resistance [6e9]. The
combination therapy with fimasartan and amlodipine can
provide synergistic effects to the hypertensive patients, since
they give different mechanisms of antihypertensive action
[3,7]. Several methods have been reported for simultaneous
determination of amlodipine with other drugs [11]. However,
chromatographic determination of amlodipine with fima-
sartan has not been addressed previously. Accordingly, inMean Concentration (µg/ml)
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Fig. 3 e Calibration curve: (A), fimasartan; (B), amlodipine.present research simultaneous determination of fimasartan
and amlodipine in tablet dosage form was developed and
validated. Furthermore, stability of active ingredients was
determined in samples stored under normal and accelerated
conditions using the described method. In this HPLC method
acetonitrile and 0.02 M monopotassium phosphate buffer (50/
50, v/v) were used as mobile phase. The chromatogram con-
taining peaks of fimasartan and amlodipine in 8min detection
time is shown in Fig. 2. The selected chromatographic condi-
tions resulted in retention of fimasartan and amlodipine at
5.24 0.03 and 2.64 0.08min (n¼ 6), respectively (Fig. 2). The
applied analytical conditions produced the peakswith suitable
peak symmetry (<2) [12].
The typical conditions for systemsuitability of ananalytical
methodencompass the relative standarddeviation (RSD)< 1%,
peak symmetry <2 and theoretical plates >2000 [12]. The re-
sults of system suitability of present chromatographicmethodTable 2 e Regression analysis.
Parameter Fimasartan Amlodipine
Slope 48745.53  417.63 51454.27  98.580
Intercept 4142  35.487 793.34  1.520
Correlation coefficient (r2) 0.9997  0.00006 0.9999  0.00004
Each value represents the Mean  S.D. (n ¼ 6).
Table 3 e Inter-day and Intra-day precision and accuracy.
Reference
value
(mg/ml)
Actual value (mg/ml)a
Fimasartan Recovery (%)a
10 9.872  0.005 98.72  0.050
15 14.883  0.011 99.22  0.073
30 29.830  0.027 99.43  0.089
Inter-day variance (% RSD)
30 29.65  0.07 0.23
Intra-day variance (% RSD)
30 29.81  0.05 (Day 1) 0.17
30 30.69  0.03 (Day 2) 0.10
30 30.84  0.08 (Day 3) 0.26
Amlodipine Recovery (%)a
0.625 0.622  0.005 99.52  0.801
1.25 1.248  0.003 99.84  0.237
2.5 2.474  0.003 98.96  0.120
Inter-day variance (% RSD)
2.5 2.520  0.006 0.24
Intra-day variance (% RSD)
2.5 2.469  0.005 (Day 1) 0.20
2.5 2.499  0.008 (Day 2) 0.32
2.5 2.589  0.002 (Day 3) 0.07
a Each value shows the Mean  S.D. (n ¼ 6).
Table 4 e Robustness testing.
Parameter Setting Fimasartana Amlodipinea
Retention time Peak area Retention time Peak area
Column temperature 36 C 5.33  0.02 1,507,397  0.34 2.95  0.02 125,920  0.70
40 C 5.24  0.03 1,501,337  0.05 2.64  0.08 125,876  0.45
44 C 5.18  0.00 1,506,172  0.05 2.59  0.02 128,219  0.93
Mobile phase flow rate 0.9 ml/min 5.35  0.01 1,668,144  0.13 2.35  0.02 141,408  0.94
1.0 ml/min 5.24  0.03 1,501,337  0.05 2.64  0.08 125,876  0.45
1.1 ml/min 5.15  0.02 1,365,454  0.08 2.56  0.04 114,959  0.16
Mobile phase pH 2.2 5.17  0.07 1,506,672  0.05 2.53  0.09 131,481  0.91
2.5 5.24  0.03 1,501,337  0.05 2.64  0.08 125,876  0.45
2.7 5.27  0.36 1,498,836  0.09 2.75  0.14 128,119  0.94
a Each value represents the Mean  %RSD of each setting (n ¼ 3).
Table 5 e Stability in sample solutions.
Time Points Peak Areaa
Fimasartan (30 mg/ml) Amlodipine (2.5 mg/ml)
1 h 149,897  0.74 125,824  0.45
2 h 1,501,336  0.61 125,976  0.70
4 h 1,506,177  0.70 128,219  0.64
8 h 1,507,387  0.45 129,131  0.71
16 h 1,510,021  0.66 130,024  0.56
32 h 1,516,525  0.58 137,161  0.82
64 h 1,519,896  0.71 139,815 0.74
a Each value denotes the Mean  %RSD (n ¼ 6).
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factor and theoretical plates were within the recommended
limits. Therefore, the method was considered as suitable.
The standard S/N ratio for LOD and LOQ in accordancewith
the ICH guidelines is 3/1 and 10/1, respectively [13]. For fima-
sartan, the present HPLC method provided S/N ratio
(mean  S.D., n ¼ 3) of 3.212  0.109 and 10.521  0.532 cor-
responding to 3.5 mg/ml and 15 mg/ml, respectively. Thus,
these were regarded as LOD and LOQ of fimasartan, respec-
tively. Likewise, the standard concentrations of amlodipine
with 0.35 mg/ml and 1.0 mg/ml furnished S/N ratio of
3.042  0.097 and 10.331  0.451 (mean  S.D., n ¼ 3),Table 6 e Stability determination (% assay) of powdered tablet
Storage conditions Initial 14 day
Fimasartan
R.T. 100.97  0.05 100.02  0.86
45 C 101.40  0.84 99.89  1.10
60 C 100.96  0.47 99.77  0.56
40 C/75%RH 101.61  1.01 99.80  1.06
UV 100.85  1.03 99.67  1.12
Amlodipine
R.T. 101.21  0.50 99.78  0.46
45 C 100.99  1.21 99.69  0.32
60 C 100.78  1.06 99.56  1.40
40 C/75%RH 101.89  1.74 99.46  3.04
UV 101.33  1.06 99.35  0.54
Each value denotes Mean  S.D. (n ¼ 3).respectively. Therefore, they were designated as LOD and LOQ
of amlodipine, respectively.
Each calibration curve was constructed with six standard
strengths (Fig. 3). The calibration curve of fimasartan was
made with 6, 12, 18, 24, 30 and 36 mg/ml concentrations
(Fig. 3A). Similarly, the concentrations used in the formation
of calibration curve of amlodipinewere 0.5, 1.0, 1.5, 2.0, 2.5 and
3.0 mg/ml (Fig. 3B). The regression analysis is displayed in
Table 2. The correlation coefficient (r2) was 0.9997 and 0.9999
for fimasartan and amlodipine, respectively.
The results of accuracy and precision (inter-day variance
and intra-day variance) are shown in Table 3. For accuracy, all
the recovery values were within 5%. The mean recovery
value of fimasartan and amlodipine was 99.12% and 99.44%,
respectively. For inter-day and intra-day variance assessment
%RSD was calculated. All the samples exhibited RSD values
<1% confirming that the analytical method was precise [12].
Table 4 reveals the results of minor modifications in
analytical conditions such as temperature of column, flow
rate of mobile phase and pH of mobile phase. No substantial
variances were observed in the retention time and peak area
of each component when the chromatographic conditions
were slightly changed one by one. Moreover, the RSD for each
valuewas<1%. Thus, the proposedmethodwas considered as
robust.samples under stress condition.
28 day 42 day 56 day
99.87  0.81 99.71  0.68 99.41  1.04
99.58  1.04 99.37  1.07 99.29  0.36
99.50  2.10 99.28  1.45 99.18  1.52
99.55  0.72 99.28  1.78 99.14  0.84
99.63  0.56 99.58  1.26 99.32  0.19
99.62  0.35 99.50  0.83 99.30  0.40
99.45  0.78 99.32  1.17 99.12  0.54
99.29  0.36 99.12  0.12 98.93  0.47
99.19  0.63 98.88  1.10 98.84  1.78
99.17  0.42 99.14  1.46 99.02  0.53
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sample solutions (constituted with acetonitrile) was per-
formed up to 64 h. The sample solutions placed in the auto-
sampler at room temperature were analysed periodically at
1, 2, 4, 8, 16, 32 and 64 h. The results are shown in Table 5. The
peak areas of each drug were not considerably different from
each other. Moreover, RSD value of each samplewas<1%. The
slight increase in peak area with the passage of time sug-
gested that small evaporation of the solvent took place
resulting in increased concentration of the sample. According
to our results the drugs dissolved in acetonitrile were stable at
room temperature during analysis over a period of 64 h.
The stability study of fimasartan and amlodipine in
powdered tablet samples placed under ambient conditions of
temperature, relative humidity and UV radiations was carried
out up to 56 days. The powdered tablet samples were sepa-
rately stored at room temperature (R.T.), 45 C, 60 C, 40 C
with 75% relative humidity (RH) and ultraviolet radiations (UV)
for investigating the influence of these conditions on fima-
sartan and amlodipine. The assay (%) of fimasartan and
amlodipine in each sample was determined and recorded
prior to exposure to these conditions. Then, the labelled
samples were stored under the above-mentioned conditions.
Each sample was assayed periodically for fimasartan and
amlodipine. The results of fimasartan and amlodipine content
(% assay) at 14, 28, 42 and 56 day are shown in Table 6. All the
values are within the 95e105%. Thus, fimasartan and amlo-
dipine were stable in combination tablet dosage form under
intentionally applied stressed conditions.4. Conclusions
The present HPLC method for simultaneous determination of
fimasartan and amlodipine proved to be simple, rapid, precise,
accurate and robust. Moreover, fimasartan and amlodipine
were found stable in the sample solutions placed at room
temperature up to 64 h. Furthermore, the drugs in the
powdered tablet samples exposed to applied conditions were
also found stable over a period 56 days. Accordingly, the
proposed analytical procedure with detection time of 8 min
can be used for reliable simultaneous determination of fima-
sartan and amlodipine in pure and tablet dosage form.
Acknowledgement
This work was supported by a grant from the Korean Health
Technology R&D Project, Ministry for Health, Welfare and
Family Affairs, Republic of Korea (A092018) and a grant from
the Medical Cluster R&D Support Project of Daegu Gyeongbuk
Medical Innovation Foundation (HT13C0011) in South Korea.r e f e r e n c e s
[1] Ezzati M, Vander Hoorn S, Lawes CM, et al. Rethinking the
“diseases of affluence” paradigm: global patterns of
nutritional risks in relation to economic development. PLoS
Med 2005;2:e133.
[2] Sica D. Rationale for fixed-dose combinations in the
treatment of hypertension. Drugs 2002;62:443e462.
[3] Sohn Y. Crystal forms of an angiotensin II receptor
antagonist BR-A657. J Therm Anal Calorim 2007;89:799e802.
[4] Chi YH, Lee H, Paik SH, et al. Safety, tolerability,
pharmacokinetics, and pharmacodynamics of fimasartan
following single and repeated oral administration in the
fasted and fed states in healthy subjects. Am J Cardiovasc
Drugs 2011;11:335e346.
[5] Kim JW, Yi S, Kim TE, et al. Increased systemic exposure of
fimasartan, an angiotensin II receptor antagonist, by
ketoconazole and rifampicin. J Clin Pharmacol
2013;53:75e81.
[6] Yi S, Kim J, Kim T, et al. Effect of multiple doses of
fimasartan, an angiotensin II receptor antagonist, on the
steady-state pharmacokinetics of digoxin in healthy
volunteers. Int J Clin Pharmacol Ther 2011;49:321e327.
[7] Yi S, Kim T-E, Yoon SH, et al. Pharmacokinetic interaction of
fimasartan, a new angiotensin II receptor antagonist, with
amlodipine in healthy volunteers. J Cardiovasc Pharmacol
2011;57:682e689.
[8] Jeon H, Lim KS, Shin K-H, et al. Assessment of the drugedrug
interactions between fimasartan and hydrochlorothiazide in
healthy volunteers. J Cardiovasc Pharmacol 2012;59:84e91.
[9] Lee SE, Kim Y-J, Lee H-Y, et al. Efficacy and tolerability of
fimasartan, a new angiotensin receptor blocker, compared
with losartan (50/100 mg): a 12-week, phase III, multicenter,
prospective, randomized, double-blind, parallel-group, dose
escalation clinical trial with an optional 12-week extension
phase in adult Korean patients with mild-to-moderate
hypertension. Clin Ther 2012;34:552e568. e9.
[10] Dongre VG, Shah SB, Karmuse PP, et al. Simultaneous
determination of metoprolol succinate and amlodipine
besylate in pharmaceutical dosage form by HPLC. J Pharm
Biomed Anal 2008;46:583e586.
[11] Mohammadi A, Rezanour N, Ansari Dogaheh M, et al.
A stability-indicating high performance liquid
chromatographic (HPLC) assay for the simultaneous
determination of atorvastatin and amlodipine in commercial
tablets. J Chromatogr B 2007;846:215e221.
[12] Shabir GA. Validation of high-performance liquid
chromatography methods for pharmaceutical analysis:
understanding the differences and similarities between
validation requirements of the US Food and Drug
Administration, the US Pharmacopeia and the International
Conference on Harmonization. J Chromatogr A
2003;987:57e66.
[13] Guideline IHT. Validation of Analytical Procedures: Text and
Methodology, Q2 (R1), Current Step 4 Version, Parent
Guidelines on Methodology Dated November 6 1996,
Incorporated in November 2005. International Conference on
Harmonisation, Geneva, Switzerland, www ich org2008.
